SOURCE: Salt Creek Ventures

February 15, 2007 12:11 ET

Salt Creek Ventures Announces the Opening of a New Facility

SAN CLEMENTE, CA -- (MARKET WIRE) -- February 15, 2007 -- The founders of Salt Creek Ventures are pleased to announce the opening of their new 4,000-square foot headquarters in San Clemente, CA. Salt Creek Ventures was formed in 2006 by the former executive management team from Vascular Control Systems (San Juan Capistrano, CA), which was acquired in May 2006 by Ethicon, Inc., a Johnson & Johnson Company. The mission of Salt Creek Ventures is to create novel medical device companies utilizing the latest advances in technology.

The Salt Creek Team, lead by Dr. Fred Burbank, has over 80 years of combined healthcare experience. Dr. Burbank is the previous founder and principal inventor of the technologies developed and commercialized by Biopsys (acquired by Ethicon Endo-Surgery, a Johnson & Johnson Company in 1997), SenoRx (Aliso Viejo, CA), and Vascular Control Systems. The remainder of the team is comprised of Greig Altieri, former CEO of Vascular Control Systems, Mike Jones, former Vice President of Research and Development, and Al Memmolo, former Vice President of Clinical and Regulatory Affairs. Together the team has experience in developing new technologies across a wide spectrum of clinical practice and applications; these include products in the areas of interventional cardiology and neurosurgery, dermatology, Women’s health and breast cancer diagnosis and treatment, drug delivery systems, radiology, urology, in-vitro diagnostics, and real-time patient monitoring.

Salt Creek Ventures seeks to partner with inventors and physicians early in the product concept phase to build new companies. We offer complete resources to the inventor; company formation and fundraising, intellectual property analysis and strategy, initial operations through completed prototypes, and laboratory and clinical testing capabilities. We are the team to successfully translate a physician’s product from concept into clinical and commercial reality.

For more information please visit

Contact Information